# Declan Doogan

> Declan Doogan is a seed investor at University College Cork backing Biopharma and Therapeutics. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [University College Cork](https://shizune.co/investors/profile/university-college-cork)
- Location: Douglas, Isle of Man
- Total investments: 3
- Last investment: Feb 2023
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/declan-doogan-65568a9a

Declan Doogan is a seed investor at University College Cork in Douglas focused on Biopharma and Therapeutics. Declan Doogan has over 30 years of industry experience in both major pharma and biotech.He was the Senior Vice-President and Head of Worldwide Development at Pfizer, where many multibillion dollar programs were delivered (e.g., Viagra, Lipitor and Zoloft). He has held a number of executive positions in Pfizer in the US, the UK and Japan. Sinceleaving Pfizer in 2007 he has been engaged in executive roles in small pharma. Declan was CMO and acting CEO of Amarin (AMRN: Nasdaq), transforming it from a failing Neuroscience company to a vibrant cardiovascular company with a market capitalization of over one billion dollars before his departure. He has also been Chief Medical Officer for Prometheus Laboratories, a molecular diagnostics company in San Diego. Declan is also an investor in emerging biotechnology and technology companies. He holds a number of Board appointments, principally in pharma companies, and has also held professorships positions at Harvard School of Public Health, Glasgow University Medical School and Kitasato University (Tokyo).Declan received his medical degree from Glasgow University in 1975. He is a Fellow of the Royal College of Physicians and the Faculty Pharmaceutical Medicine and holds a Doctorate of Science at the University of Kent in the UK.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biopharma | 2 | 67% |
| Therapeutics | 2 | 67% |
| Biotechnology | 2 | 67% |
| Health Care | 1 | 33% |
| Pharmaceutical | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 33% |
| Series A | 1 | 33% |
| Venture - Series Unknown | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 1 | 33% |
| United Kingdom | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Causeway Therapeutics | A bio pharmaceutical spin out emerging from the University of Glasgow, working in the orthobiologic therapeutic space. Intellectual property has been generated via academic research demonstrating a proven mechanistic reasoning for the use of a microRNA therapy in the treatment of tendinopathies. | $10.5M | Venture - Series Unknown | Feb 22, 2023 |  |
| Causeway Therapeutics | A bio pharmaceutical spin out emerging from the University of Glasgow, working in the orthobiologic therapeutic space. Intellectual property has been generated via academic research demonstrating a proven mechanistic reasoning for the use of a microRNA therapy in the treatment of tendinopathies. | $1.3M | Seed | Aug 03, 2017 |  |
| Intensity Therapeutics | Intensity Therapeutics, Inc., a biopharmaceutical company, provides chemotherapy treatments for cancer patients. It engages in the direct intratumoral injection of novel pharmaceutical formulations for cancer administration. Intensity Therapeutics, Inc. was incorporated in 2012 and is based in Norwalk, Connecticut. | $10M | Series A | Jun 28, 2016 |  |

3 of 3 investments shown.

## Co-investors
- [Scottish Investment Bank](https://shizune.co/investors/profile/scottish-investment-bank) — VC Fund, 2 deals together
- [Batterson Venture Capital](https://shizune.co/investors/profile/batterson-venture-capita) — VC Fund, 1 deal together
- [Glasgow University Holdings](https://shizune.co/investors/profile/glasgow-university-holdings) — VC Fund, 1 deal together
- [Mediqventures](https://shizune.co/investors/profile/mediqventures) — VC Fund, 1 deal together
- [SalvaRx Group PLC](https://shizune.co/investors/profile/salvarx-group-plc) — VC Fund, 1 deal together
- [VCapital](https://shizune.co/investors/profile/vcapital) — VC Fund, 1 deal together

## About University College Cork

VC Fund · Cork, Ireland

University College Cork is a higher education institution. The new college's location was dramatic and picturesque, perched on the edge of a limestone bluff overlooking. At the turn of the twentieth century, it was clear that higher education in Ireland required a new arrangement to allow for the next stages of development.

5 contacts available at University College Cork.

| Name | Title | Profile |
| --- | --- | --- |
| Alan Duncan | Associate Faculty, Business Information Systems | https://shizune.co/investors/profile/alan-duncan-3 |
| Declan Doogan | Adjunct Professor of Psychiatry | https://shizune.co/investors/profile/declan-doogan |
| Eugene Crehan | External Examiner UCC - Higher Diploma in Leadership Development | https://shizune.co/investors/profile/eugene-crehan |
| John Cryan | Professor & Chair, Dept. Anatomy & Neuroscience; Vice President for Research & Innovation | https://shizune.co/investors/profile/john-cryan-2 |
| Klaas-Jan Stol | Lecturer | https://shizune.co/investors/profile/klaas-jan-stol |

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [Biotech Angel Investors in United Kingdom](https://shizune.co/investors/biotech-angel-investors-united-kingdom)

## FAQ

### What does Declan Doogan invest in?

Declan Doogan invests primarily in Biopharma, Therapeutics and Biotechnology startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Declan Doogan last invest?

The most recent investment recorded for Declan Doogan closed in Feb 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co